



PATENT
2806 (89188.0007)

UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Peter C. Brooks

Serial No: 09/478,977

Filed: January 6, 2000

For: METHOD AND COMPOSITION
FOR ANGIOGENESIS INHIBITION

Art Unit: 1642

Examiner: Harris, Alana M.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450, on
August 10, 2004
Date of Deposit
Olga Berson, Reg. No. 55,001
Name
<i>Olga Berson</i> 08/10/2004

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

1. The information disclosure statement submitted herewith is being filed within three months of the filing date of the application other than a continued prosecution application, or within three months of the date of entry into the national stage of an international application, or before the mailing date of a first Office Action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under §1.114, whichever event occurs last. 37 C.F.R. §1.97(b).
2. The information disclosure statement transmitted herewith is being filed *after* the period specified in §1.97(b), but *before* the mailing date of a final action under §1.113, or a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, whichever occurs first. A statement specified in §1.97(e) or a fee set forth in §1.17(p) is included. 37 C.F.R. §1.97(c).

§1.97(e) STATEMENT

I, the person signing below, state:

- that each item of information contained in the information disclosure statement was first cited in the attached communication from a foreign patent office in a counterpart foreign application and that the communication is dated not more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(1).

OR

- that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification

after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(2).

OR FEE

- Attached is a fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c). (\$180.00). [OR:] Please charge the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00) to Deposit Account No. 50-1314. A copy of this petition is enclosed.
3. The information disclosure statement transmitted herewith is being filed *after* the period specified in §1.97(c), but before, or simultaneously with the payment of the issue fee. A statement specified in §1.97(e) and a fee set forth in §1.17(p) are included. 37 C.F.R. §1.97(d).

§1.97(e) STATEMENT

I, the person signing below, state:

- that each item of information contained in the information disclosure statement was first cited in the attached communication from a foreign patent office in a counterpart foreign application and that the communication is dated not more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(1).

OR

- that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement. 37 C.F.R. §1.97(e)(2).

AND FEE

- Attached is a fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(d). (\$180.00).
4. If it should be determined that for any reason either an insufficient fee or an excessive has been paid, please charge any insufficiency or credit any overpayment necessary to ensure consideration of the information disclosure statement for the above-identified application to Deposit Account No. 50-1314. **A copy of this petition is enclosed.**

5. A list of 10 reference(s) is in the enclosed Form PTO-1449.

Respectfully submitted,
HOGAN & HARTSON L.L.P.

By: Olga Berson
Olga Berson, Ph.D.
Registration No. 55,001
Attorney for Applicant(s)

Date: August 10, 2004

Biltmore Tower
500 South Grand Avenue, Suite 1900
Los Angeles, CA 90071
Telephone: (213) 337-6700
Facsimile: (213) 337-6701

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Applicant

Peter C. Brooks

AUG 16 2004
(Use several sheets if necessary)

Filing Date

January 6, 2000

Group Art Unit

1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Borza, Dorin-Bogdan, et al., "Identification of Multiple Cryptic Epitopes on the NC1 Domain of the a3(IV) Collagen Chain," The Journal of Biological Chemistry, Vol. 275, No. 8, February 25, 2000, pp. 6030-6037
	David, Michelle, et al., "Hydrophobic Amino Acid Residues Are Critical for the Immunodominant Epitope of the Goodpasture Autoantigen," The Journal of Biological Chemistry, Vol. 276, No. 9, 2001, pp. 6370-6377
	Greenspan, Neil S., et al., "Defining Epitopes: It's Not As Easy As It Seems," Nature Biotechnology, Vol. 17, October, 1999, pp. 936-937
	Kalluri, Raghu, et al. "Specificity of Circulating and Tissue-Bound Autoantibodies in Goodpasture Syndrome," Proceedings of the Association of American Physicians, 1996, pp. 135-139
	Mariuzza, R.A., et al. "The Structural Basis of Antigen-Antibody Recognition," Am. Rev. Biophys., Biophys. Chem. 1987, pp. 139-159
	Nakanishi, Koichi, et al., "Immunohistochemical Study of a1-5 Chains of Type IV Collagen in Hereditary Nephritis," Kidney International, Vol. 46, 1994, pp. 1413-1421
	Wheatcroft, A.C., "Evidence of In Situ Stability of the Type IV Collagen Triple Helix in Human Inflammatory Bowel Disease Using a Denaturation Specific Epitope Antibody," Matrix Biology 18, 1999, pp. 361-372
	Yang, Wei-Ping, et al., "CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range," J. Mol. Biol., 1995, 254, pp. 392-403
	Yoshioka, Kazuo, et al., "Normal Distribution and Abnormalities in X-Linked Alport Syndrome Revealed by Monoclonal Antibody," American Journal of Pathology, Vol. 144, No. 5, 1994, pp. 986-996
	Xu, Jingson, et al., "Generation of Monoclonal Antibodies to Cryptic Collagen Sites by Using Subtractive Immunization," Hybridoma, Vol. 19, November 5, 2000, pp. 375-385

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.